用McAb—AST对黑热病患者疗效考核的进一步研究

THE FURTHER STUDY ON EVALUATION OF EFFICACY OF ANTI—KALA—AZAR TREATMENT BY MCAB—AST

用单克隆抗体一抗原斑点试验(McAb—AST)对我国山丘疫区27例(32人次)黑热病患者在斯锑黑克治疗前、后检测循环抗原作了对比观察,以考核疗效。其中25例治前骨髓涂片查见病原体,2例骨髓片漏诊。32人次治疗前MeAb—AST均显阳性反应。一个疗程后McAb—AST转为阴性的16人次,临床表现为痊愈,McAb—AST仍为阳性反应的9例,临床表现也未愈;余7人次McAb—AST与临床症状均有一定程度好转。本法显示的结果与患者病情的归转状况及病原体的查获与否是相吻合的。表明McAb—AST可用于黑热病治后近期疗效考核,且可弥补骨髓涂片的漏诊。

In order to develop a sensitive and specific for assessment of efficacy of anti—kala—azar treatment, 27 cases were detected comparatively before and after antimony treatment by McAb—AST with the McAb 1B_1—C_2 which had been obtained 7 years ago by the authers. Among those 27 patients, 25 had been found amastigotes in bone marrow, and all the cases showed positive McAb—AST before the treatment. After a course of treatment, the results of McAb—AST were that 16 cases were shown negative with clinically complete cure of kala—azar; the results of McAb—AST showed in concordance with the different clinical manifestation of kala—azar and the presence of pathogen. The McAb—AST may be used as a promising method for evaluating the efficacy of treatment as well as to remedy missing—diagnosis by bone marrow smear method and it is also easy to use in the field with the simple procedure.